Race CEO Dr Daniel Tillett sits down with Juliette Saly at ausbiz for a check-in on the company’s performance in the last quarter, and the outlook for the rest of the year.

Dr Tillett says one of the most notable achievements in the quarter was the news that Race’s RC220 bisantrene formulation met all cGMP specifications required for a human IV drug product.

Dr Tillet also discusses how strong shareholder support has put the company in a healthy financial position to deliver on its clinical development program, including its upcoming trial in solid tumours.

You can also watch the full interview here.